Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Meiji Seika Pharma Co. Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This prosecution activity is concentrated under 1 distinct examiner, CHASE, CAROL ANN. This indicates a focused portfolio relative to the 1 distinct examiner assigned. Such a narrow distribution suggests that the company's current patent strategy is localized within a specific technical niche rather than being spread across multiple departments of the USPTO. This concentration allows for direct engagement with the assigned examiner during the prosecution process.
The busiest examiner, CHASE, CAROL ANN, is responsible for the 1 busiest examiner pending case. This activity is situated within 1 distinct art unit, meaning the company's immediate success in this field depends on a specific point of review. For a practitioner, this indicates a centralized prosecution environment relative to the 1 distinct art unit involved, where examiner-specific trends will significantly impact the portfolio's trajectory. The lack of diversity in examiners simplifies the monitoring process but increases the impact of the examiner's perspective on the overall portfolio. The resolution of this 1 pending office action will determine the immediate status of the company's filings. Future filings may either continue this focused trend or expand into broader categories within the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHASE, CAROL ANN | 1 | 41.9% | +84.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18041818 | ANTI-CLEAVED MUTANT CALR-CD3 BISPECIFIC ANTIBODY AND PHARMACEUTICAL COMPOSITION | CHASE, CAROL ANN | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18041818 | ANTI-CLEAVED MUTANT CALR-CD3 BISPECIFIC ANTIBODY AND PHARMACEUTICAL COMPOSITION | CHASE, CAROL ANN | 1646 | §112 | Final Rejection | — | Pending | Feb 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMeiji Seika Pharma Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Carol Ann Chase has the most, with 1 of Meiji Seika Pharma Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
